In this second part of a 2-part series on the global burden of cardiovascular disease, we
review the proven, effective approaches to the prevention and treatment of cardiovascular …

Aims Recent trials have examined the effect of prolonged dual antiplatelet therapy (DAPT) in
a variety of patient populations, with heterogeneous results regarding benefit and safety …

Background The potential benefit of dual antiplatelet therapy beyond 1 year after a
myocardial infarction has not been established. We investigated the efficacy and safety of …

ESC Guidelines 3002 recommendations. To implement the guidelines, condensed pocket
guidelines versions, summary slides, booklets with essential messages, and an electronic …

It is important that the medical profession play a significant role in critically evaluating the
use of diagnostic procedures and therapies as they are introduced and tested in the …

Background Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine
diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet …

The ACC/AHA Task Force on Practice Guidelines was formed to make recommendations
regarding the diagnosis and treatment of patients with known or suspected cardiovascular …

Background Clopidogrel and aspirin are widely used for patients with acute coronary
syndromes and those undergoing percutaneous coronary intervention (PCI). However …

Background Despite improvements in the emergency treatment of myocardial infarction (MI),
early mortality and morbidity remain high. The antiplatelet agent clopidogrel adds to the …

The content of these European Society of Cardiology (ESC) Guidelines has been published
for personal and educational use only. No commercial use is authorized. No part of the ESC …